摘要:
A rosuvastatin calcium intermediate as shown by Formula I is prepared as follow: a) subjecting chloroethylene, magnesium and R-epoxy chloropropane to Grignard reaction, b) adding sodium cyanide for nucleophilic substitution reaction, c) adding alcohol for alcoholysis reaction, d) adding alkaline solvent for hydroxyl protection, e) subjecting the mixture to oxidation reaction, f) adding triphenyl phosphorus and subjecting to Wittig reaction in the presence of alkali to obtain the compound of formula I. The method has moderate reaction conditions, is convenient and stable and can be applied to industrial production.
摘要:
The invention relates to cyclopentadienylphosphazene complexes (CpPN complexes) of metals of the III. and VI. group and of the lanthanoids except for lutetium. The complexes of the invention are isolobal and isoelectric with respect to the [(CpSiN)TiR2] complexes. There is exactly one CpPN moiety in the complexes of the invention. The cyclopentadienyl moiety of CpPN represents a monodentate, anionic ligand of the metal atom in all complexes of the invention. The metal atom is also bound to other anionic ligands. In a preferred embodiment, both the cyclopenadienyl moiety and the nitrogen atom within CpPN bind to the metal atom so that CpPN represents a bidentate ligand. Complexes in which CpN represents a bidentate ligand are CpPN Constrained Geometry Complexes (CpPN-CGC). The invention also relates to methods for producing the complexes in situ. The CpPN complexes can be electrically neutral or be present as cationic complexes. Cationic complexes are formed when one of the other anionic ligands of the metal atom is replaced by a neutral ligand; counterions of the cationic CpPN complexes are preferably fluoroborate, tetraphenyl borate, tetrakis-(3,5-trifluormethylphenyl)borate. The complexes are produced in situ by reacting a metal halide with a protonated cyclopentadienylphosphazene CpPNH and an alkaline or alkaline earth salt of the desired other anionic ligand. The complexes according to the invention can be used as catalysts for the hydroamination and polymerization of polyolefins.
摘要:
The invention relates to a micro-engineered reactor device comprising a closely coupled reactor and electrochemical cell, and a method of using such a reactor for the synthesis of organic compounds by a process involving an electrochemical reaction. The synthetic processes are of a type in which a source material is electrochemically converted to a reactive primary product which is exposed at a reaction region within a channel, or chamber, to a precursor material so that the primary product and precursor material react to generate a secondary product.
摘要:
A process is disclosed for producing α-chlor-methylen-triorganylphosphorane carboxylic acid derivatives having the formula (I), in which R stands for C organic substituents; A stands for CN or CO-B; B stands for C or O organic residues that remain inert in chlorinating conditions, by chlorinating phosphoranes having the formula (II) with chlorine. Chlorination is carried out in the presence of a mineral base as hydrogen chloride acceptor, whereas chlorine and the base are synchronously but separately introduced into the reaction mixture according to their consumption. The products (I) obtained by this process represent important intermediates for plant protective substances.
摘要:
Herstellung von α-Chlor-phosphoryliden der Formel I in der die Reste Ar gleiche oder verschiedene Arylgruppen bedeuten und E für einen das Ylid (I) stabilisierenden Substituenten steht, durch Umsetzung eines Phosphoniumsalzes der allgemeinen Formel II in welcher Hal Chlor, Brom oder Iod bedeutet, mit einem Chlorierungsmittel, indem man als Chlorierungsmittel Chlorkalk verwendet.
摘要:
The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
摘要:
or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra′, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.